The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated ...

Abrysvo, which is now the first maternal RSV vaccine to be prequalified by the organisation, aims to prevent RSV-associated ...

Early data suggests that the respiratory syncytial virus (RSV) vaccination programme is significantly reducing hospital admissions among ...

With the RSV season officially underway in South Africa, experts are urging healthcare providers to prepare for an influx of ...

Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...

A new study published in the Journal of American Medical Association showed that nirsevimab offers protection against a ...

Gov. Phil Murphy said the cuts would create "an unfillable void in funding that will have disastrous ramifications for our ...

On 12 March 2025, the World Health Organization (WHO) prequalified the first maternal respiratory syncytial virus (RSV) vaccine to protect infants ...

Historically, RSV has been studied mainly in infants and older adults, but recent research shows that it also poses a ...